Report of specific cardiovascular outcomes of the ADVANTAGE trial [2]

Annals of Internal Medicine

Volumn 143, Issue 2, 2005, Pages 158-159

  Braunstein, Ned ^a   Polis, Adam ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; ROFECOXIB;

ACUTE HEART INFARCTION; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LUNG EMBOLISM; PRIORITY JOURNAL; SIDE EFFECT; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 22244469769     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-2-200507190-00118     Document Type: Letter

References (5)

1. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139:539-46. [PMID: 14530224]
2. FDA Advisory Committee Background Information. Presented to Arthritis Advisory Committee. 8 February 2001. Accessed at www.fda.gov/ohrms/dockets/ac/ 01/briefing /3677b2_01_merck.pdf on 9 June 2005.
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106. [PMID: 8298418]
4. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001; 104:2280-8. [PMID: 11696466]
5. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003; 146:591-604. [PMID: 14564311]